University of Alcalá

About: University of Alcalá is a education organization based out in Alcalá de Henares, Spain. It is known for research contribution in the topics: Population & Context (language use). The organization has 10795 authors who have published 20718 publications receiving 410089 citations. The organization is also known as: University of Alcala & University of Alcala de Henares.

The economics of wind energy

Abstract: This article presents the outcomes of a recent study carried out among wind energy manufacturers and developers regarding the current generation costs of wind energy projects in Europe, the factors that most influence them, as well as the reasons behind their recent increase and their expected future evolution. The research finds that the generation costs of an onshore wind farm are between 4.5 and 8.7 scent/kWh; 6–11.1 scent/kWh when located offshore, with the number of full hours and the level of capital cost being the most influencing elements. Generation costs have increased by more than 20% over the last 3 years mainly due to a rise of the price of certain strategic raw materials at a time when the global demand has boomed. However, the competitive position of wind energy investments vis-a ` -vis other technologies has not been altered. In the long-term, one would expect production costs go down; whether this will be enough to offset the higher price of inputs will largely depend on the application of correct policies, like RD introduction of advanced siting and forecasting techniques; access to adequate funding; and long-term legal stability.

Permafrost is warming at a global scale

Abstract: Permafrost warming has the potential to amplify global climate change, because when frozen sediments thaw it unlocks soil organic carbon. Yet to date, no globally consistent assessment of permafrost temperature change has been compiled. Here we use a global data set of permafrost temperature time series from the Global Terrestrial Network for Permafrost to evaluate temperature change across permafrost regions for the period since the International Polar Year (2007–2009). During the reference decade between 2007 and 2016, ground temperature near the depth of zero annual amplitude in the continuous permafrost zone increased by 0.39 ± 0.15 °C. Over the same period, discontinuous permafrost warmed by 0.20 ± 0.10 °C. Permafrost in mountains warmed by 0.19 ± 0.05 °C and in Antarctica by 0.37 ± 0.10 °C. Globally, permafrost temperature increased by 0.29 ± 0.12 °C. The observed trend follows the Arctic amplification of air temperature increase in the Northern Hemisphere. In the discontinuous zone, however, ground warming occurred due to increased snow thickness while air temperature remained statistically unchanged.

Massive molecular outflows and evidence for AGN feedback from CO observations

Abstract: We study the properties of massive, galactic-scale outflows of molecular gas and investigate their impact on galaxy evolution. We present new IRAMPdBI CO(1-0) observations of local ultra-luminous infrared galaxies (ULIRGs) and quasar-hosts: a clear signature of massive and energetic molecular outflows, extending on kpc scales, is found in the CO(1-0) kinematics of four out of seven sources, with measured outflow rates of several 100M(circle dot)yr(-1). We combine these new observations with data from the literature, and explore the nature and origin of massive molecular outflows within an extended sample of 19 local galaxies. We find that starburst-dominated galaxies have an outflow rate comparable to their star formation rate (SFR), or even higher by a factor of similar to 2-4, implying that starbursts can indeed be effective in removing cold gas from galaxies. Nevertheless, our results suggest that the presence of an active galactic nucleus (AGN) can boost the outflow rate by a large factor, which is found to increase with the L-AGN/L-bol ratio. The gas depletion time scales due to molecular outflows are anti-correlated with the presence and luminosity of an AGN in these galaxies, and range from a few hundred million years in starburst galaxies down to just a few million years in galaxies hosting powerful AGNs. In quasar hosts, the depletion time scales due to the outflow are much shorter than the depletion time scales due to star formation. We estimate the outflow kinetic power and find that, for galaxies hosting powerful AGNs, it corresponds to about 5% of the AGN luminosity, as expected by models of AGN feedback. Moreover, we find that momentum rates of about 20 L-AGN/c are common among the AGN-dominated sources in our sample. For "pure" starburst galaxies, our data tentatively support models in which outflows are mostly momentum-driven by the radiation pressure from young stars onto dusty clouds. Overall, our results indicate that, although starbursts are effective in powering massive molecular outflows, the presence of an AGN may strongly enhance such outflows, and therefore have a profound feedback effect on the evolution of galaxies by efficiently removing fuel for star formation, hence quenching star formation.

TRY plant trait database : Enhanced coverage and open access

Abstract: Plant traits-the morphological, anatomical, physiological, biochemical and phenological characteristics of plants-determine how plants respond to environmental factors, affect other trophic levels, and influence ecosystem properties and their benefits and detriments to people. Plant trait data thus represent the basis for a vast area of research spanning from evolutionary biology, community and functional ecology, to biodiversity conservation, ecosystem and landscape management, restoration, biogeography and earth system modelling. Since its foundation in 2007, the TRY database of plant traits has grown continuously. It now provides unprecedented data coverage under an open access data policy and is the main plant trait database used by the research community worldwide. Increasingly, the TRY database also supports new frontiers of trait-based plant research, including the identification of data gaps and the subsequent mobilization or measurement of new data. To support this development, in this article we evaluate the extent of the trait data compiled in TRY and analyse emerging patterns of data coverage and representativeness. Best species coverage is achieved for categorical traits-almost complete coverage for 'plant growth form'. However, most traits relevant for ecology and vegetation modelling are characterized by continuous intraspecific variation and trait-environmental relationships. These traits have to be measured on individual plants in their respective environment. Despite unprecedented data coverage, we observe a humbling lack of completeness and representativeness of these continuous traits in many aspects. We, therefore, conclude that reducing data gaps and biases in the TRY database remains a key challenge and requires a coordinated approach to data mobilization and trait measurements. This can only be achieved in collaboration with other initiatives.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Abstract: Summary Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood–brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials. Methods An integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0–2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG ( NCT02650401 ; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov , NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012–000148–88 (ALKA-372-001). Findings Patients were enrolled in ALKA-372–001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77–18·76). 31 (57%; 95% CI 43·2–70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred. Interpretation Entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours. Funding Ignyta/F Hoffmann-La Roche.